Figure 2 from High-Dose Intravenous Vitamin C Combined with Docetaxel in Men with Metastatic Castration-Resistant Prostate Cancer: A Randomized Placebo-Controlled Phase II Trial

<p>Key secondary endpoints. Key secondary endpoints include rPFS, OS, duration of PSA response, and quality of life measured using the FACT-P instrument. <b>A,</b> rPFS and (<b>B</b>) OS are presented for docetaxel + HDIVC vs. docetaxel + placebo. The KM method was used to estimate the median, 12-month, and 24-month rates of rPFS and OS. <b>C,</b> Duration of PSA response and (<b>D</b>) FACT-P scores are presented for docetaxel + HDIVC vs. docetaxel + placebo.</p>

Duke Scholars

Author Christopher Hoimes Medicine, Medical Oncology